Cybin Inc. (NEO: CYBN) Acquisition, Three-Pillar Approach Reason for Optimistic MDD Outlook

by NASDAQ Market News December 17, 2020

NASDAQ Market News
Click here to email author

Tarsier Pharma’s Positive End-of-Phase 2 Meeting with the U.S. FDA Sets Stage for TRS01 Phase III Program in Uveitis

Albireo Initiates Global Phase 3 Clinical Trial of Odevixibat in Alagille Syndrome

Ads